Joe Grossman

[Agenus @Agenus_Bio]

When standard options are exhausted, access matters.

France has expanded compassionate access to #BOT+ BAL for patients with colorectal cancer, certain ovarian cancers, and soft-tissue sarcomas—fully reimbursed and hospital-based under AAC.
Read Release: https://t.co/kqD3gNHL73

[Dr. Ben Johnson @Benjohnson1112]

Exciting momentum for BOT/BAL @myESMO: durable immune activation ➡️ survival benefit across difficult to treat tumors including MSS CRC -https://t.co/2g2csYVw6l
Now, phase 3 BATTMAN begins! BOT/BAL in refractory MSS mCRC @jonathanloree @Agenus_Bio @CDNCancerTrials @OncoAlert

[Agenus @Agenus_Bio]

Emerging survival plateaus with BOT/BAL across advanced solid tumors.

Presented by Dr. Michael Gordon at #ESMO2025 from a 400+ patient Phase 1b study of refractory cancers.

See the full presentation → https://t.co/RrXNv940FO
#BOTBAL #ImmunoOncology

[Agenus @Agenus_Bio]

Today at #AACR25, Dr. @MyriamChalabi presented the first results from the NEOASIS study, evaluating neoadjuvant botensilimab/balstilimab in early-stage MSS and MSI-H cancers, including colorectal and breast cancers.

Learn more: https://t.co/ZNMPtfPQJc.

#Oncology #ClinicalTrial

[Cancer Discovery @CD_AACR]

From the December issue: Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, Is Effective Against Tumors Poorly Responsive to Conventional Immunotherapy https://t.co/E2eGyQ3iFk

By @dhanschand and colleagues @Agenus_Bio

[Jennifer Buell @jbuell01]

🚨 NEW in @JCO_ASCO shows promise for advanced sarcomas
Combining #BOT/#BAL:
✅ ORR: 19.2% (all sarcomas)
✅ ORR: 27.8% (angiosarcoma)
✅ Durable responses: 21.7 months median DOR
✅ Manageable safety
Kudos to Dr. @breelynwilkyMD , @Agenus_Bio & team https://t.co/ogjLWGyJEY

[Dr. Marwan G. Fakih @mgfakih]

Today, at GI ASCO, I had the privilege of presenting the results of R Phase 2 study of BOT +/- BAL in chemoresistant MSS CRC- an area in dire need of treatment options. BOT75/BAL240 ORR 19%, DCR 55%. BAL value confirmed. Majority study responses ongoing. DURABLE responses matter

[Dr. Ben Johnson @Benjohnson1112]

✅ BOT/BAL IST data in the neoadjuvant colon setting @#GI25 ! 🚨mPR & pCR rates acheived and confirmed now in 2 independent trials pave the way for next generation clinical trial designs for our pts. let’s change the course of CRC together👏🏽👏🏽@FoundationGono @mdmanishshah @ASCO

[Oncoinfo @Oncoinfo_it]

🎤 Elisa Fontana (UK) intervista Filippo Ghelardi (IT) sui risultati di GONO UNICORN: solo 1 ciclo con il nuovo anti-CTLA4 botensilimab + anti-PD1 balstilimab dà risposte maggiori o complete nel cancro del colon MSS e 93% di eradicazione completa in MSI.#GI25 #Oncology

[Pashtoon Kasi MD, MS @pashtoonkasi]

🆕#GI25 abstracts now released! 📰 🗞️

Neoadjuvant #immunotherapy continues to impress! Building upon the paradigm shift of immunotherapy to earlier settings ➡️📈CURES🙌🏽

✅NEST🪺
✅UNICORN🦄
✅NICHE

These trials📚~80 treated. ✔️SAFE.
🔜Time for a phase-2/3.
@OncoAlert #CRCSM

[Nicholas Hornstein @GIMedOnc]

#GI25
Neoadjuvant immunotherapy for MSS storms the stage.
Amazing responses to Bot + Bal @Agenus_Bio
Can’t wait for the Phase III (or a accelerated approval; I can dream)
This will be a game changer for MSS CRC.
Congrats @pashtoonkasi

[Dr. Marwan G. Fakih @mgfakih]

GI/ASCO: We presented our Phase 1 BOT/BAL with FOLFOX in MSS MCRC. 14 patients on the phase 1 study. 10 had prior Ox and 12 had prior chemo, yet ORR was 10/14 patients (majority of the pts had liver mets). The combination was safe with 2 doses of BOT + Q2w FOLFOXBEV/BAT

[Agenus @Agenus_Bio]

Results from our Phase 1 clinical trial on the combination of botensilimab and balstilimab for MSS mCRC have been published in @NatureMedicine. Read the full publication here: https://t.co/KN6bDp3eWX

[Joe Grossman @JoeGrossman7]

Botensilimab and balstilimab in MSS CRC, just out in Nature Medicine: https://t.co/y1xGeys5Yg

[Pashtoon Kasi MD, MS @pashtoonkasi]

🆕🗞️Just out
🪺#NEST-1 trial results👇🏾

Are we on the verge of a new drug combo for colon or rectal cancer?

Substantial & brisk responses to just☝🏾dose of BOT🟢➕BAL🔹🔹 immunotherapy.🙌🏾

Pattern & kill is unprecedented🌊.

@ASCO #GI24 @OncoAlert
Abstract 117📍Poster Board H2

[Joe Grossman @JoeGrossman7]

Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer | Oncogene https://t.co/Ai3jtUAzog

[Agenus @Agenus_Bio]

Today, Dr. Andrea Bullock presented positive data showing the survival benefit of botensilimab & balstilimab in #patients with advanced #colorectalcancer.

Learn more here: https://t.co/3KrJWB61hh

@BIDMChealth #WCGIC23

[David Faleck @DavidFaleckMD]

Thanks for highlighting, was a great group effort.

@MPostow @MSKCancerCenter @drmoniquetello @JoeGrossman7 #mikedougan @JCO_ASCO

[ClinicalOncologyNews @ClinOncNews]

Botensilimab plus balstilimab improves outcomes in recurrent platinum-resistant/-refractory ovarian cancer.
https://t.co/CSndAK8nQw @SGO_org @BrunoBockorny @sitcancer

[OncLive.com @OncLive]

PD-1/CTLA-4 Combination Drives Progress Across Tumor Types @BrunoBockorny @ben_schlechter @BIDMChealth @harvardmed @DanaFarber #oncology https://t.co/045xY8BasM